Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2023—LGC Clinical Diagnostics has launched the Seraseq gDNA BRCA1/2 LGR Somatic Mutation Mix and Seraseq gDNA BRCA1/2 LGR Inherited Mutation Mix. The products are intended for use as quality reference materials in developing, validating, and evaluating the routine performance of laboratory tests and are for research use only.
March 2023—Verichem Laboratories announced the availability of ready-to-use, multilevel clinical reference materials intended for use with toxicology assays on a range of wet chemistry analyzers.
March 2023—Qiagen has launched its QIAseq Platform Partnership program and a partnership with Sophia Genetics that will bring together QIAseq reagent technology for next-generation sequencing with the Sophia DDM digital analytics platform. The Platform Partnership program aims to enhance the use and compatibility of QIAseq NGS kits to support secondary analysis and tertiary interpretation workflows offered by other digital data-sharing and analytics companies. The kits are designed for use with any sequencer.
March 2023—Anavasi Diagnostics announced FDA emergency use authorization for its AscencioDx COVID-19 test and AscencioDx molecular detector for use in POC settings operating under a CLIA certificate of waiver, certificate of compliance, or certificate of accreditation. The system uses reverse transcription loop-mediated isothermal amplification for the qualitative detection of RNA from the COVID-19 virus in samples that are heated and illuminated via fluorescence signals in a reaction tube placed within the detector. Results are available in as few as 20 minutes. The detector is reusable for at least 3,000 test cycles, the company says, and is powered by a 12-volt adapter.
March 2023—Verichem Laboratories’ ready-to-use Enzyme ER Calibration Verifier kit is now available. The materials are designed for the calibration verification of enzyme assays on wet chemistry testing systems and contain nine clinical enzyme components covering 54 individual activity levels. The enzyme components within the materials include amylase, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, cholinesterase, creatine phosphokinase, gamma glutamyltransferase, lactate dehydrogenase, and lipase. The materials are intended to be treated as patient specimens and have a shelf life of 18 months.
March 2023—Globe Scientific has introduced a line of Globe/Euromex microscopes and microscope accessories. The line is composed of 24 CE-certified stereoscopic, compound, and inverted binocular and trinocular microscopes and 12 microscope accessories. Customers can access several support tools, including a microscope selection guide and Euromex Academy, which includes online video tutorials, user manuals, educational blogs, and more.
March 2023—PerkinElmer debuted its Zephyr G3 NGS iQ workstation at the Society for Laboratory Automation and Screening conference in San Diego, Feb. 25–March 1. The system enables the automated construction of up to 96 NGS libraries and is composed of a high-performing liquid handler, integrated thermocycler, robotic arm, and deck accessories and peripherals. The workstation is available with an optional cloud-based software to further simplify creating and editing NGS protocols, the company says, by using a single pane of glass interface and developing methods from scientific intent rather than code.
March 2023—BD announced FDA market approval for the Onclarity HPV assay to be used with the Hologic ThinPrep Pap test. The Onclarity HPV assay detects and identifies 14 high-risk human papillomavirus types in a single analysis. The assay reports genotypes 16, 18, 31, 45, 51, 52, 33/58, 35/39/68, and 56/59/66, and has FDA approval for use in vaccinated women.
March 2023—LGC SeraCare has developed three contrived, tumor normal cell-line–derived homologous recombinant deficiency reference materials: Seraseq FFPE HRD High-Positive RM, Seraseq FFPE HRD Low-Positive RM, and Seraseq FFPE HRD Negative RM.
March 2023—Flagship Biosciences announced a partnership with Genomenon in which Genomenon’s Mastermind knowledge base will provide disease-specific genomic data sets to enrich Flagship’s genomic profiling services. The partnership aims to accelerate biomarker discovery and companion diagnostics development solutions and improve patient stratification for clinical trials and treatment selection.
